For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
1
views
10
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      261
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Evaluation of the impact of anaemia on quality of life among breast cancer patients undergoing chemotherapy in Malaysia

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          The purpose of this study was to evaluate the impact of anaemia on the quality of life (QOL) among breast cancer patients.

          Methods

          A total of 120 anaemic (haemoglobin < 12 g/dL) breast cancer patients were identified through chart review. Patients were followed-up for three cycles of chemotherapy filled in a QOL questionnaire Functional Assessment Chronic Therapy –Anaemia at each follow-up session. Data such as haemoglobin Hb levels and chemotherapy regimens were also recorded on each follow-up. Data were analysed using SPSS.

          Key findings

          The Hb level and QOL mean scores of all follow-ups were 10.34 ± 0.73 g/dL and 96.37 ± 16.15 g/dL, respectively. QOL was adversely affected by anaemia severity, and the curves declined significantly from the first follow-up to the third follow-up (P < 0.001).

          Conclusion

          It is crucial to consider developing a guideline for the treatment of anaemia, which is not available currently, and improve the QOL for the wellbeing of cancer patients.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

          Matthew E Kaplan, D Cella, Lorraine Webster … (1997)
          This paper reports the development and validation of a questionnaire assessing fatigue and anemia-related concerns in people with cancer. Using the 28-item Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire as a base, 20 additional questions related to the symptoms and concerns of patients with anemia were developed. Thirteen of these 20 questions dealt with fatigue, while the remaining 7 covered other concerns related to anemia. Using semi-structured interviews with 14 anemic oncology patients and 5 oncology experts, two instruments were produced: The FACT-Fatigue (FACT-F), consisting of the FACT-G plus 13 fatigue items, and the FACT-Anemia (FACT-An), consisting of the FACT-F plus 7 nonfatigue items. These measures were, in turn, tested on a second sample of 50 cancer patients with hemoglobin levels ranging from 7 to 15.9 g/dL. The 41-item FACT-F and the 48 item FACT-An scores were found to be stable (test-retest r = 0.87 for both) and internally consistent (coefficient alpha range = 0.95-0.96). The symptom-specific subscales also showed good stability (test-retest r range = 0.84-0.90), and the Fatigue subscale showed strong internal consistency (coefficient alpha range = 0.93-0.95). Internal consistency of the miscellaneous nonfatigue items was lower but acceptable (alpha range = 0.59-0.70), particularly in light of their strong relationship to patient-rated performance status and hemoglobin level. Convergent and discriminant validity testing revealed a significant positive relationship with other known measures of fatigue, a significant negative relationship with vigor, and a predicted lack of relationship with social desirability. The total scores of both scales differentiated patients by hemoglobin level (p < 0.05) and patient-rated performance status (p < 0.0001). The 13-item Fatigue subscale of the FACT-F and the 7 nonfatigue items of the FACT-An also differentiated patients by hemoglobin level (p < 0.05) and patient-rated performance status (p < or = 0.001). The FACT-F and FACT-An are useful measures of quality of life in cancer treatment, adding more focus to the problems of fatigue and anemia. The Fatigue Subscale may also stand alone as a very brief, but reliable and valid measure of fatigue.
          Article 0 comments Cited 241 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The Cancer Patient and Quality of Life

            A Bottomley (2002)
            Article 0 comments Cited 44 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Recent Update in the Pathogenesis and Treatment of Chemotherapy and Cancer Induced Anemia

              Hikmat Abdel-Razeq, Hasan Hashem (2019)
              Cancer and chemotherapy-induced anemia (CIA) is commonly encountered among patients undergoing active chemotherapy with or without radiation therapy. Its pathogenesis is complex and is often difficult to identify. Symptoms related to CIA may have a negative impact on quality of life and may influence treatment efficacy, disease progression and even survival. The recent major setback of erythropoietin-stimulating agents (ESAs) and the reluctance to transfuse cancer patients with mild and even moderate anemia, had resulted in significant under-treatment of CIA. The discovery of hepcidin and its role in iron homeostasis has revolutionized our understanding of the pathogenesis of iron deficiency and iron overload states. In the present review we examine the multifactorial pathogenesis of CIA, addressing the main mechanisms by which the tumor and immune system affect anemia. Additionally, we discuss the treatment options with more focus on the utilization of the new intravenous iron formulations for this indication.
              Article 0 comments Cited 26 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Fares Mohammed Saeed Muthanna: (View ORCID Profile)
                Ali Haider Mohammed: (View ORCID Profile)
                Journal
                Title: Journal of Pharmaceutical Health Services Research
                Publisher: Oxford University Press (OUP)
                ISSN (Electronic): 1759-8893
                Publication date Created: June 01 2021
                Publication date Created: May 10 2021
                Publication date Created: January 23 2021
                Publication date Other: June 01 2021
                Publication date (Print): May 10 2021
                Publication date (Electronic): January 23 2021
                Volume: 12
                Issue: 2
                Pages: 310-312
                Affiliations
                [1 ]Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, Selangor, Malaysia
                [2 ]Department of Pharmacy, Al Rafidain University College, Baghdad, Iraq
                [3 ]School of Pharmacy, Monash University Malaysia, Selangor, Malaysia
                Article
                DOI: 10.1093/jphsr/rmaa033
                SO-VID: c506fcd1-d7c0-40d4-8757-b3de693e8c75
                Copyright © © 2021
                License:

                https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

                History

                Data availability:

                Comments

                Comment on this article